Accessibility Menu
Mera Pharmaceuticals logo

Mera Pharmaceuticals

(OTC) MRPI

Current Price$0.00
Market Cap$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1990)-100%
5 Year-100%
1 Year+0%
1 Month-99%

Mera Pharmaceuticals Financials at a Glance

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$302.62K

Net Income (TTM)

-$187.68K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-13.05 (Low)

Price

$0.00

Volume

4,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

MRPI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mera Pharmaceuticals

Industry

Biotechnology

Headquarters

Las Vegas, NV 89123, US

MRPI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

536.65M

Volume

4.00K

Avg. Volume

2.33K

Financials (TTM)

Gross Profit

$286.36K

Operating Income

-$201.05K

EBITDA

-$187.76K

Operating Cash Flow

-$71.84K

Capital Expenditure

$0.00

Free Cash Flow

-$74.13K

Cash & ST Invst.

$4.32K

Total Debt

$0.00

Mera Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2011YOY CHG

Revenue

$63.92K

-0.4%

Gross Profit

$61.68K

+116.6%

Gross Margin

96.51%

N/A

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.76

N/A

Employees

74

N/A

Net Income

-$102.19K

+74.1%

EBITDA

-$101.43K

+74.1%

Quarterly Fundamentals

Name
Q4 2011YOY CHG

Total Cash

$4.32K

-27.4%

Total Debt

$0.00

N/A

Accounts Receivable

$7.85K

-11.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

0.00%

N/A

Return on Invested Capital

18.75%

N/A

Free Cash Flow

-$72.19K

+50.2%

Operating Cash Flow

-$72.19K

-1518.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ONBIONE Bio Corp.
$0.00+0.00%
LADXLadRx Corporation
$0.01-89.72%
MHTXManhattan Scientifics, Inc.
$0.00+0.00%
DNAGDNAPrint Genomics, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PATHUiPath
$11.68-0.01%
FRMIFermi
$6.59-0.10%
ONDSOndas
$7.26-0.05%
NOKNokia
$12.44-0.04%

Questions About MRPI

What is the current price of Mera Pharmaceuticals?

Mera Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Mera Pharmaceuticals?

Over the past 52 weeks, Mera Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Mera Pharmaceuticals have?

Mera Pharmaceuticals total debt is unavailable.

How much cash does Mera Pharmaceuticals have on hand?

Mera Pharmaceuticals does not have cash on hand data available.

What is Mera Pharmaceuticals’s dividend yield?

Mera Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.